Bottom line
Is JEHSX a good fund? The bottom line
JEHSX is the Series I share class of Health Sciences Trust, a managed health care sector mutual fund from John Hancock.
It charges 1.04% — about $104 a year on every $10,000 invested, more expensive than 56% of health care sector funds we track.
It returned +19.5% over one year, +4.2% a year over five years, +8.7% a year over ten (as of Dec 31, 2025, per its prospectus).
With $251 million in net assets and 173 holdings, its largest position is Eli Lilly and Company (14.3%) and the top 10 make up 48.3% of the portfolio.
The closest lower-cost alternative we found is XLV (0.08%, 80% top-holdings overlap).
What to watch
- 12b-1 marketing fee of 0.05% a year
Updated Nov 19, 2026
What JEHSX invests in
To seek long-term capital appreciation.
Under normal market conditions, the fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in common stocks of companies engaged, at the time of investment, in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively, health sciences). (The fund will provide written notice to shareholders at least 60 days prior to a change in its 80% investment policy.) While the fund may invest in companies of any size, the majority of its assets are expected to be invested in large- and mid-cap companies. The subadvisors portfolio managers divide the health sciences sector into four main areas: pharmaceutical companies, health care services companies, medical products and devices providers, and biotechnology firms. Their allocation among these four areas will vary depending on…
From the fund's prospectus (filed Apr 15, 2026).
JEHSX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| JEHSX | +19.5% | +4.2% | +8.7% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What JEHSX costs
On a $10,000 investment, JEHSX's 1.04% expense ratio costs about $104 a year. The prospectus estimates $1,282 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
JEHSX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly and Company LLY US | 14.30% |
| 2 | Johnson and Johnson JNJ US | 6.33% |
| 3 | UnitedHealth Group Incorporated UNH US | 5.95% |
| 4 | AbbVie Inc. ABBV US | 5.28% |
| 5 | Merck and Co. Inc. MRK US | 4.21% |
| 6 | Gilead Sciences Inc. GILD US | 2.95% |
| 7 | Thermo Fisher Scientific Inc. TMO US | 2.67% |
| 8 | Vertex Pharmaceuticals Incorporated VRTX US | 2.38% |
| 9 | Bristol-Myers Squibb Company BMY US | 2.22% |
| 10 | Abbott Laboratories ABT US | 2.00% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 48.3% of the fund. See all top 25 holdings and asset mix →
Alternatives to JEHSX
| Family | Fund | Expense ratio | Overlap | |
|---|---|---|---|---|
| SPDR (State Street) | XLV State Street(R) Health Care Select… | 0.08% | 80% | Compare |
| Fidelity | FHLC Fidelity MSCI Health Care Index ETF | 0.084% | 78% | Compare |
| Vanguard | VHT Vanguard Health Care Index Fund | 0.09% | 79% | Compare |
| iShares | IYH iShares U.S. Healthcare ETF | 0.37% | 77% | Compare |
| J.P. Morgan | JDOC JPMorgan Healthcare Leaders ETF | 0.65% | 58% | Compare |
| Schwab | SWHFX Schwab Health Care Fund | 0.8% | 73% | Compare |